Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: sustained release tacrolimus given once daily: sustained release tacrolimus given once daily compared against conventional twice daily tacrolimus,
Sustained release Tacrolimus 1 mg OD
Sponsors
Amrita Institute of medical sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients above 18 years 2. Patients who are recipient of primary liver allografts from a living donor. 3. Patients who are capable of understanding and giving written informed consent to be a part of the study.
Exclusion criteria
Exclusion criteria: 1. Deceased donor liver transplant recepients 2. Multiorgan transplants 3. ABO incompatible grafts 4. Recent chemotherapy before transplantation 5. Intolerance to study medications 6. Pediatric transplant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The primary endpoint is eGFR estimated by CKD-EPI and cystatin clearance at 1,3 and 6 monthsTimepoint: 1,3 and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Biopsy proven acute cellular rejectionTimepoint: Within 6 months post transplant;New onset diabetes mellitus,New onset systemic hypertension and Hypercholesterolemia. Timepoint: Within 6 months post transplant;Post transplant graft function , Patient survival and graft survival, Post transplant infectious complications, Post transplant hospital stay, Post transplant biliary or vascular complications, Incidence of tremor and neurotoxicityTimepoint: Within 6 months post transplant;Serum tacrolimus levels attainedTimepoint: Measured twice weekly in first month, then once in two weeks for next two months and then monthly | — |
Countries
India
Contacts
Public ContactGuhan V
Amrita institute of medical sciences
Outcome results
None listed